GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Shares Outstanding (EOP)

Kintara Therapeutics (STU:3DMA) Shares Outstanding (EOP) : 10.17 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Kintara Therapeutics's shares outstanding for the quarter that ended in Dec. 2023 was 10.17 Mil.

Kintara Therapeutics's quarterly shares outstanding increased from Sep. 2023 (1.75 Mil) to Dec. 2023 (10.17 Mil). It means Kintara Therapeutics issued new shares from Sep. 2023 to Dec. 2023 .

Kintara Therapeutics's annual shares outstanding increased from Jun. 2022 (1.31 Mil) to Jun. 2023 (1.69 Mil). It means Kintara Therapeutics issued new shares from Jun. 2022 to Jun. 2023 .


Kintara Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Kintara Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Shares Outstanding (EOP) Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.23 0.65 1.31 1.69

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.69 1.69 1.75 10.17

Competitive Comparison of Kintara Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Kintara Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Shares Outstanding (EOP) falls into.



Kintara Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Kintara Therapeutics  (STU:3DMA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Kintara Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines